clinical trial · NCT05244304
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Stargardt Disease 1TinlarebantPlacebo
brief summary
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
started
Mar 28, 2022
primary completion
Aug 4, 2025
completion
Sep 12, 2025
last updated
Oct 31, 2025
detailed description
Approximately 90 subjects will be enrolled in this study. Subjects will be assigned to study drug (tinlarebant 5 mg/placebo) with treatment period of upto 24 months with 28 days of follow-up.
official title
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol